Antoine Thiery-Vuillemin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antoine Thiery-Vuillemin has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Florence Joly
Medical Oncology Department, Centre Francois Baclesse, Caen, France
2 shared publications A. Ozatilgan
Sanofi US, Cambridge, USA
1 shared publication- Alain Ruffion
Urology Department, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon Cancer Innovation Center (EA 3738 CICLY), Lyon Sud Medical School, University of Lyon 1, Lyon, France
1 shared publication - Alan Barnicle
Translational Medicine, Oncology R&D, AstraZeneca, Cambridge Biomedical Campus, Cambridge, UK
1 shared publication Ayse Ozatilgan
Sanofi US, Cambridge, Massachusetts, USA
1 shared publication- Berangère Narciso
Tours University Hospital, Service d'oncologie médicale, 2 Bd Tonnellé, 37000, Tours, France
1 shared publication
Latest Publications
- 13 January 2023
- Published by Elsevier in European Journal of Cancer
- Vol. 182, 66-76
Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study
- 13 January 2023
- Published by Elsevier in European Journal of Cancer
- Vol. 182, 66-76
Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study
- Open Access
- 24 November 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-11
TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma
Background: Urothelial carcinoma (UC) is the ninth most commonly diagnosed cancer worldwide, with a 3.8/1 male to female ratio. Platinum-based chemotherapy is the first line standard of care for fit patients with advanced UC. However, despite a response rate (RR) for approximately half of patients receiving standard chemotherapy, durable responses are rare (median progression-free progression (PFS) around 8 months). Recently, immune checkpoint inhibitors (ICI) have emerged as new therapeutic options. Among them, Avelumab, an anti-PD-L1 antibody, was assessed in maintenance treatment, demonstrating an overall survival improvement in the JAVELIN Bladder-100 phase III trial. These findings led to its approval as first line maintenance therapy for patients with locally advanced or metastatic UC who have not progressed on prior platinum-containing chemotherapy. However, disease progression as best response was noticed for 37% of patients under Avelumab as maintenance treatment. UC has targetable genomic alterations, including DNA damage repair (DDR) alterations. DDR deficiency is known to major sensitivity to both platinum-based chemotherapy and PD-1/PD-L1 blockade and the combination of ICI and PARP inhibitors showed promising results. It therefore warrants to assess the interest of combining ICI plus PARP inhibitors as maintenance treatment in UC patients. Methods: The TALASUR trial is a single-arm multicenter phase 2 study aiming to assess the antitumor activity of the combination of Avelumab with Talazoparib among patients with locally advanced/metastatic UC in maintenance therapy after platinum-based chemotherapy. The primary objective is to determine the efficacy of the combination, assessed through PFS. Secondary objectives are as follows: safety profile of the association, objective response, duration of tumoral response, disease control rate, time to subsequent therapy, quality of life. A blood and tumor collections will be also constituted. Patient will receive the combination therapy of daily oral Talazoparib (1 mg/day) and intra-venous Avelumab 800 mg on days 1 and 15, in a 28-day cycle. Fifty patients will be enrolled. Discussion: Talazoparib with Avelumab combination may have additive activity when administrated jointly. We hypothesize that combination will increase the antitumor activity in UC first line maintenance setting with an acceptable safety profile. Trial registration: NCT04678362, registered December 21, 2020. Protocol version: Version 1.3 dated from 2020 09 11.
- 24 November 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-11
Open AccessTALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma
Background: Urothelial carcinoma (UC) is the ninth most commonly diagnosed cancer worldwide, with a 3.8/1 male to female ratio. Platinum-based chemotherapy is the first line standard of care for fit patients with advanced UC. However, despite a response rate (RR) for approximately half of patients receiving standard chemotherapy, durable responses are rare (median progression-free progression (PFS) around 8 months). Recently, immune checkpoint inhibitors (ICI) have emerged as new therapeutic options. Among them, Avelumab, an anti-PD-L1 antibody, was assessed in maintenance treatment, demonstrating an overall survival improvement in the JAVELIN Bladder-100 phase III trial. These findings led to its approval as first line maintenance therapy for patients with locally advanced or metastatic UC who have not progressed on prior platinum-containing chemotherapy. However, disease progression as best response was noticed for 37% of patients under Avelumab as maintenance treatment. UC has targetable genomic alterations, including DNA damage repair (DDR) alterations. DDR deficiency is known to major sensitivity to both platinum-based chemotherapy and PD-1/PD-L1 blockade and the combination of ICI and PARP inhibitors showed promising results. It therefore warrants to assess the interest of combining ICI plus PARP inhibitors as maintenance treatment in UC patients. Methods: The TALASUR trial is a single-arm multicenter phase 2 study aiming to assess the antitumor activity of the combination of Avelumab with Talazoparib among patients with locally advanced/metastatic UC in maintenance therapy after platinum-based chemotherapy. The primary objective is to determine the efficacy of the combination, assessed through PFS. Secondary objectives are as follows: safety profile of the association, objective response, duration of tumoral response, disease control rate, time to subsequent therapy, quality of life. A blood and tumor collections will be also constituted. Patient will receive the combination therapy of daily oral Talazoparib (1 mg/day) and intra-venous Avelumab 800 mg on days 1 and 15, in a 28-day cycle. Fifty patients will be enrolled. Discussion: Talazoparib with Avelumab combination may have additive activity when administrated jointly. We hypothesize that combination will increase the antitumor activity in UC first line maintenance setting with an acceptable safety profile. Trial registration: NCT04678362, registered December 21, 2020. Protocol version: Version 1.3 dated from 2020 09 11.
- 24 July 2022
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 20 (6) , 533-542
Management and Health Resource Use of Patients With Metastatic Renal Cell Carcinoma treated With Systemic Therapy Over 2014-2017 in France: A National Real-World Study
- 24 July 2022
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 20 (6) , 533-542
Management and Health Resource Use of Patients With Metastatic Renal Cell Carcinoma treated With Systemic Therapy Over 2014-2017 in France: A National Real-World Study
- Open Access
- 21 March 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (6) , 1734
PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
Despite recent improvements in survival, metastatic castration-resistant prostate cancers (mCRPCs) remain lethal. Alterations in genes involved in the homologous recombination repair (HRR) pathway are associated with poor prognosis. Poly-ADP-ribose polymerase (PARP) inhibitors (PARPis) have demonstrated anti-tumoral effects by synthetic lethality in patients with mCRPCs harboring HRR gene alterations, in particular BRCA2. While both olaparib and rucaparib have obtained government approvals for use, the selection of eligible patients as well as the prescription of these treatments within the clinical urology community are challenging. This review proposes a brief review of the rationale and outcomes of PARPi treatment, then a pragmatic vision of PARPi use in terms of prescription and the selection of patients based on molecular screening, which can involve potential genetic counseling in the case of associated germinal alterations.
- 21 March 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (6) , 1734
Open AccessPARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
Despite recent improvements in survival, metastatic castration-resistant prostate cancers (mCRPCs) remain lethal. Alterations in genes involved in the homologous recombination repair (HRR) pathway are associated with poor prognosis. Poly-ADP-ribose polymerase (PARP) inhibitors (PARPis) have demonstrated anti-tumoral effects by synthetic lethality in patients with mCRPCs harboring HRR gene alterations, in particular BRCA2. While both olaparib and rucaparib have obtained government approvals for use, the selection of eligible patients as well as the prescription of these treatments within the clinical urology community are challenging. This review proposes a brief review of the rationale and outcomes of PARPi treatment, then a pragmatic vision of PARPi use in terms of prescription and the selection of patients based on molecular screening, which can involve potential genetic counseling in the case of associated germinal alterations.
- Open Access
Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer
Background: Phase III randomized trial data have confirmed the activity for olaparib in homologous recombination repair (HRR) mutated metastatic castration-resistant prostate cancer (mCRPC) post next-generation hormonal agent (NHA) progression. Preclinical data have suggested the potential for a combined effect between olaparib and NHAs irrespective of whether an HRR gene alteration was present. NCT01972217 was a randomised double-blind Phase II study which evaluated olaparib and abiraterone versus placebo and abiraterone in mCRPC patients who had received prior chemotherapy containing docetaxel. The study showed that radiologic progression was significantly delayed by the combination of olaparib and abiraterone regardless of homologous recombination repair mutation (HRRm) status. The study utilized tumour, blood (germline), and circulating tumour DNA (ctDNA) analysis to profile patient HRRm status, but tumour tissue provision was not mandated, leading to relatively low tissue acquisition and DNA sequencing success rates not representative of real-world testing. Patients and methods: Further analysis of germline and ctDNA samples has been performed for the trial to characterize HRRm status more fully and robustly analyse patient response to treatment. Results: Germline and plasma testing increased the HRRm characterized population from 27% to 68% of 142 randomized patients. Tumour-derived variants were detectable with high confidence in 78% of patients with a baseline plasma sample (71% of randomized patients). There was high concordance across methodologies (plasma vs. tumour; plasma vs. germline). The HR for the exploratory analysis of radiographic progression-free survival was 0.54 (95% CI: 0.32–0.93) in favour of olaparib and abiraterone in the updated HRR wild type (HRRwt) group (n = 73) and 0.62 (95% CI: 0.23–1.65) in the HRRm group (n = 23). Conclusion: Our results confirm the value of plasma testing for HRRm status when there is insufficient high-quality tissue for multi-gene molecular testing. We show that patients with mCRPC benefit from the combination of olaparib and abiraterone treatment regardless of HRRm status. The combination is currently being further investigated in the Phase III PROpel trial.
Open AccessHomologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer
Background: Phase III randomized trial data have confirmed the activity for olaparib in homologous recombination repair (HRR) mutated metastatic castration-resistant prostate cancer (mCRPC) post next-generation hormonal agent (NHA) progression. Preclinical data have suggested the potential for a combined effect between olaparib and NHAs irrespective of whether an HRR gene alteration was present. NCT01972217 was a randomised double-blind Phase II study which evaluated olaparib and abiraterone versus placebo and abiraterone in mCRPC patients who had received prior chemotherapy containing docetaxel. The study showed that radiologic progression was significantly delayed by the combination of olaparib and abiraterone regardless of homologous recombination repair mutation (HRRm) status. The study utilized tumour, blood (germline), and circulating tumour DNA (ctDNA) analysis to profile patient HRRm status, but tumour tissue provision was not mandated, leading to relatively low tissue acquisition and DNA sequencing success rates not representative of real-world testing. Patients and methods: Further analysis of germline and ctDNA samples has been performed for the trial to characterize HRRm status more fully and robustly analyse patient response to treatment. Results: Germline and plasma testing increased the HRRm characterized population from 27% to 68% of 142 randomized patients. Tumour-derived variants were detectable with high confidence in 78% of patients with a baseline plasma sample (71% of randomized patients). There was high concordance across methodologies (plasma vs. tumour; plasma vs. germline). The HR for the exploratory analysis of radiographic progression-free survival was 0.54 (95% CI: 0.32–0.93) in favour of olaparib and abiraterone in the updated HRR wild type (HRRwt) group (n = 73) and 0.62 (95% CI: 0.23–1.65) in the HRRm group (n = 23). Conclusion: Our results confirm the value of plasma testing for HRRm status when there is insufficient high-quality tissue for multi-gene molecular testing. We show that patients with mCRPC benefit from the combination of olaparib and abiraterone treatment regardless of HRRm status. The combination is currently being further investigated in the Phase III PROpel trial.
- Open Access
- 27 April 2021
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 26 (7) , e1179-e1188
Post Hoc Health-Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies
Background The phase III PROSELICA (NCT01308580) and FIRSTANA (NCT01308567) trials investigated taxane chemotherapy among men with post‐docetaxel metastatic castration‐resistant prostate cancer (mCRPC) or chemotherapy‐naïve mCRPC, respectively. We present a post hoc analysis of patient reported health‐related quality of life (HRQL) among patients with or without a clinical (pain, tumor or prostate‐specific antigen [PSA]) response. Materials and Methods PROSELICA and FIRSTANA HRQL and pain data were collected and analyzed using protocol‐defined Functional Assessment of Cancer Therapy Prostate (FACT‐P) and McGill‐Melzack (Present Pain Intensity scale) questionnaires. Outcomes included definitive FACT‐P total score (TS) improvements and longitudinal assessment of FACT‐P TS. Results In PROSELICA and FIRSTANA, the proportion of patients receiving taxane chemotherapy with a definitive FACT‐P TS improvement was significantly higher among patients with vs without a pain or PSA response (pain: PROSELICA: 67% vs 33.5%, p < 0.001; FIRSTANA: 75.2% vs 45.8%, p < 0.001; PSA: PROSELICA: 50.3% vs 34.2%, p < 0.001; FIRSTANA: 49.8% vs 38.9%, p = 0.001). In PROSELICA, the proportion of patients receiving taxane chemotherapy with a definitive FACT‐P TS improvement was significantly higher among patients with vs without a tumor response; the proportion was numerically higher in FIRSTANA (PROSELICA: 54.4% vs 36.7%, p = 0.001; FIRSTANA: 50.6% vs 45.3%). FACT‐P TS was significantly improved or maintained for the majority of treatment cycles analyzed. Conclusions In PROSELICA and FIRSTANA, HRQL improvements were significantly higher among patients with a pain, tumor or PSA response vs those without, with the exception of patients with a tumor response in FIRSTANA. Implications for practice Using data from the FIRSTANA and PROSELICA phase III clinical trials we demonstrate that patients with metastatic castration‐resistant prostate cancer (mCRPC) receiving docetaxel or cabazitaxel, who exhibited a response (pain, tumor, PSA), often experienced significantly greater improvements in health‐related quality of life (HRQL) compared with patients without a response. For patients with a pain response, significant HRQL improvements occurred early and were maintained. This study provides further insight into the impact of taxane chemotherapy on the HRQL of patients with mCRPC and allows for a better understanding of the relationship between treatment, response and HRQL, supporting therapeutic decision making.
- 27 April 2021
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 26 (7) , e1179-e1188
Open AccessPost Hoc Health-Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies
Background The phase III PROSELICA (NCT01308580) and FIRSTANA (NCT01308567) trials investigated taxane chemotherapy among men with post‐docetaxel metastatic castration‐resistant prostate cancer (mCRPC) or chemotherapy‐naïve mCRPC, respectively. We present a post hoc analysis of patient reported health‐related quality of life (HRQL) among patients with or without a clinical (pain, tumor or prostate‐specific antigen [PSA]) response. Materials and Methods PROSELICA and FIRSTANA HRQL and pain data were collected and analyzed using protocol‐defined Functional Assessment of Cancer Therapy Prostate (FACT‐P) and McGill‐Melzack (Present Pain Intensity scale) questionnaires. Outcomes included definitive FACT‐P total score (TS) improvements and longitudinal assessment of FACT‐P TS. Results In PROSELICA and FIRSTANA, the proportion of patients receiving taxane chemotherapy with a definitive FACT‐P TS improvement was significantly higher among patients with vs without a pain or PSA response (pain: PROSELICA: 67% vs 33.5%, p < 0.001; FIRSTANA: 75.2% vs 45.8%, p < 0.001; PSA: PROSELICA: 50.3% vs 34.2%, p < 0.001; FIRSTANA: 49.8% vs 38.9%, p = 0.001). In PROSELICA, the proportion of patients receiving taxane chemotherapy with a definitive FACT‐P TS improvement was significantly higher among patients with vs without a tumor response; the proportion was numerically higher in FIRSTANA (PROSELICA: 54.4% vs 36.7%, p = 0.001; FIRSTANA: 50.6% vs 45.3%). FACT‐P TS was significantly improved or maintained for the majority of treatment cycles analyzed. Conclusions In PROSELICA and FIRSTANA, HRQL improvements were significantly higher among patients with a pain, tumor or PSA response vs those without, with the exception of patients with a tumor response in FIRSTANA. Implications for practice Using data from the FIRSTANA and PROSELICA phase III clinical trials we demonstrate that patients with metastatic castration‐resistant prostate cancer (mCRPC) receiving docetaxel or cabazitaxel, who exhibited a response (pain, tumor, PSA), often experienced significantly greater improvements in health‐related quality of life (HRQL) compared with patients without a response. For patients with a pain response, significant HRQL improvements occurred early and were maintained. This study provides further insight into the impact of taxane chemotherapy on the HRQL of patients with mCRPC and allows for a better understanding of the relationship between treatment, response and HRQL, supporting therapeutic decision making.
- Open Access
- 28 September 2020
- Published by Morressier GmbH
Final overall survival (OS) analysis of PROfound: olaparib vs physician's choice of enzalutamide or abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations
Introduction and objectives: The Phase III randomized, open-label PROfound trial (NCT02987543) met its primary endpoint of significantly prolonged radiographic progression-free survival with olaparib vs physician’s choice of enzalutamide or abiraterone (control arm) in patients with mCRPC with progression on prior therapy and alterations in BRCA1, BRCA2 or ATM (Cohort A), and in
- 28 September 2020
- Published by Morressier GmbH
Open AccessFinal overall survival (OS) analysis of PROfound: olaparib vs physician's choice of enzalutamide or abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations
Introduction and objectives: The Phase III randomized, open-label PROfound trial (NCT02987543) met its primary endpoint of significantly prolonged radiographic progression-free survival with olaparib vs physician’s choice of enzalutamide or abiraterone (control arm) in patients with mCRPC with progression on prior therapy and alterations in BRCA1, BRCA2 or ATM (Cohort A), and in